ArticleAlzheimer's & dementia (Amsterdam, Netherlands)
Validation of regression-based change formulae for mild cognitive impairment and Alzheimer's disease.
Article in Alzheimer's & dementia (Amsterdam, Netherlands). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Multimodal biomarker characterization of amnestic objective subtle cognitive decline in aging and preclinical Alzheimer's disease.The journal of prevention of Alzheimer's disease · 2026Observational
- Characterizing and validating 12-month reliable cognitive change in Early-Onset Alzheimer's Disease for use in clinical trials.The journal of prevention of Alzheimer's disease · 2025Article
- Validation of regression-based change formulae for mild cognitive impairment and Alzheimer's disease.Alzheimer's & dementia (Amsterdam, Netherlands)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
introductionIdentification of cognitive decline is critical in older adults at risk for dementia. In a 2020 study reported in
methodsUsing longitudinal data on 5974 participants (cognitively unimpaired, mild cognitive impairment, dementia) from the National Alzheimer's Coordinating Center, SRB change scores were calculated for each individual and compared across groups.
resultsAcross 6 to 24 months, minimal cognitive change was observed in cognitively unimpaired participants. Modest declines were seen in those with mild cognitive impairment and substantial declines in those with dementia. Change scores were negatively correlated with the Clinical Dementia Rating scale. In impaired individuals, SRB scores indicated more decline in those with positive amyloid scans. DISCUSSION: Validation of SRB scores affords greater confidence in employing them in clinical and research settings. Highlights: Validation of regression-based cognitive change scores in impaired samples.Clear differences on change scores across three groups (intact, MCI, dementia).Largely stable scores in intact participants, but notable decline in MCI and dementia.Moderate to strong relationship between change scores and the Clinical Dementia Rating scale sum of boxes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.